Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of "Buy" by Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have received an average rating of "Buy" from the ten ratings firms that are currently covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $46.43.

DNTH has been the topic of several recent analyst reports. Raymond James upgraded Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday, December 12th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They issued a "buy" rating for the company. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Finally, Oppenheimer increased their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, November 11th.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock traded down $0.26 on Friday, hitting $22.74. The company had a trading volume of 258,811 shares, compared to its average volume of 205,991. Dianthus Therapeutics has a 52 week low of $10.02 and a 52 week high of $33.77. The company has a market cap of $673.04 million, a PE ratio of -9.10 and a beta of 1.74. The business has a 50-day simple moving average of $25.23 and a 200-day simple moving average of $26.66.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, equities research analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several large investors have recently made changes to their positions in the business. Janus Henderson Group PLC grew its position in Dianthus Therapeutics by 40.5% during the third quarter. Janus Henderson Group PLC now owns 949,334 shares of the company's stock worth $25,936,000 after buying an additional 273,670 shares in the last quarter. State Street Corp grew its holdings in shares of Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company's stock worth $22,483,000 after purchasing an additional 413,425 shares in the last quarter. Great Point Partners LLC grew its holdings in shares of Dianthus Therapeutics by 21.3% during the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company's stock worth $19,615,000 after purchasing an additional 132,929 shares in the last quarter. Braidwell LP increased its position in shares of Dianthus Therapeutics by 34.6% during the third quarter. Braidwell LP now owns 493,687 shares of the company's stock valued at $13,517,000 after purchasing an additional 126,836 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in shares of Dianthus Therapeutics by 151.3% in the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company's stock valued at $11,984,000 after purchasing an additional 263,500 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.